1256 related articles for article (PubMed ID: 8667049)
1. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
2. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
6. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
8. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
Urbannek V; Voth E; Moka D; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
[TBL] [Abstract][Full Text] [Related]
9. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
10. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
11. [Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy].
Moka D; Voth E; Schicha H
Nuklearmedizin; 1997 Apr; 36(3):87-92. PubMed ID: 9162907
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
[TBL] [Abstract][Full Text] [Related]
14. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.
Ruchała M; Sowiński J; Dolata M; Junik R; Gembicki M; Skiba A
Nucl Med Rev Cent East Eur; 2005; 8(1):28-32. PubMed ID: 15977144
[TBL] [Abstract][Full Text] [Related]
15. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.
Walter MA; Schindler C; Christ-Crain M; Müller-Brand J; Müller B
Eur J Clin Invest; 2009 Jan; 39(1):51-7. PubMed ID: 19087129
[TBL] [Abstract][Full Text] [Related]
16. [Clinical aspects, diagnosis and drug therapy of hyperthyroidism].
Bürgi U; Gerber H; Peter HJ
Schweiz Med Wochenschr; 1995 Aug; 125(31-32):1489-94. PubMed ID: 7545825
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
[TBL] [Abstract][Full Text] [Related]
18. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
Gedik O; Ozdemir T; Akalin S
Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.
Nygaard B; Jarløv AE; Kristensen LO; Faber J
Horm Metab Res; 2000 Jul; 32(7):283-7. PubMed ID: 10965935
[TBL] [Abstract][Full Text] [Related]
20. A simplified method for treating Graves' disease with radioactive 131I.
Masri MT; Menne M; Rooney BL; Caplan RH
Wis Med J; 1995 Jan; 94(1):21-5. PubMed ID: 7871797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]